Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs

Bullboard Posts

Comment by commissionson Mar 24, 2004 1:59pm

237 Views

Post# 7259307

RE: 100 million in Revenue

Spoke to a Canaccord broker today and this seller was in early and got a warrant with every share, so he is selling his stock at what looks to be a 50% profit and is going to ride his warrants up.Again just be happy that this dickhead settled on .65 rather than $1 or more when it would of been a lot harder to get rid of him. VERY FRUSTRATING but the stock price always catches up to the value, sometimes it takes longer but it will get there.

Bullboard Posts

BMO launches enhanced platform with tools for options trading